{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:28:52Z","timestamp":1749144532411,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT","award":["NRF-2021R1F1A1045417"],"award-info":[{"award-number":["NRF-2021R1F1A1045417"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We present a case of retinal occlusive vasculitis following brolucizumab administration and the first report of optical coherence tomography angiography (OCTA) findings after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 71-year-old man complained of vision loss in the left eye 6\u00a0weeks after brolucizumab injection. His visual acuity was counting fingers, and examination revealed 1\u2009+\u2009anterior chamber cells with 2\u2009+\u2009vitreous cells. Fundus examination demonstrated vitreous haze, retinal whitening, and vascular sheathing. Fluorescein angiography revealed filling defects in the retinal arteries and veins, and OCTA showed extensive capillary nonperfusion. Under the diagnosis of brolucizumab-associated intraocular inflammation (IOI) and retinal occlusive vasculitis, topical, sub-Tenon, and systemic corticosteroids were administered. After the treatment, visual acuity improved to 20\/200, and OCTA revealed gradual improvement in capillary dropout; however, with the limited improvement of reperfusion in the perifoveal areas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prompt evaluation and intensive corticosteroid treatments are required for brolucizumab-associated IOI. OCTA imaging provides detailed information on microvascular changes in the retinal vascular plexuses in brolucizumab-associated retinal occlusive vasculitis.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02465-0","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:25:29Z","timestamp":1654255529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-1235","authenticated-orcid":false,"given":"Eun Kyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek-Lok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Ki","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Un Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"2465_CR1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment vegf inhibitor rth258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123:1080\u20139.","journal-title":"Ophthalmology"},{"key":"2465_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296\u2013304.","journal-title":"Ophthalmology"},{"key":"2465_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"2465_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963\u201376.","journal-title":"Ophthalmology"},{"key":"2465_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"2465_CR6","unstructured":"Beovu\u00ae [US prescribing information] East Hanover NN. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761125s000lbl.pdf. Last accessed on September 1, 2021."},{"key":"2465_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345\u201359.","journal-title":"Ophthalmology"},{"key":"2465_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687","volume":"18","author":"A Jain","year":"2020","unstructured":"Jain A, Chea S, Matsumiya W, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2465_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4:269\u201379.","journal-title":"J Vitreoretin Dis"},{"key":"2465_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680","volume":"18","author":"SJ Haug","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2465_CR11","unstructured":"Safety of Beovu\u00ae (brolucizumab). https:\/\/www.brolucizumab.info\/. Last accessed on September 1, 2021."},{"key":"2465_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mones","year":"2021","unstructured":"Mones J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"},{"key":"2465_CR13","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ophtha.2015.03.016","volume":"122","author":"AJ Witkin","year":"2015","unstructured":"Witkin AJ, Shah AR, Engstrom RE, et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015;122:1438\u201351.","journal-title":"Ophthalmology"},{"key":"2465_CR14","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency assessment report EMA\/23630\/2020. https:\/\/www.emaeuropaeu\/en\/documents\/assessment-report\/beovu-epar-public-assessment-report_enpdf. Last accessed on September 1, 2021."},{"key":"2465_CR15","first-page":"1","volume":"20","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Understanding Retinal Vasculitis associated with Brolucizumab: complex Pathophysiology or Occam\u2019s Razor? Ocul Immunol Inflamm. 2021;20:1\u20133.","journal-title":"Ocul Immunol Inflamm."},{"key":"2465_CR16","unstructured":"Study of safety and efficacy of brolucizumab 6 mg dosed every 4 weeks compared to aflibercept 2 mg dosed every 4 weeks in patients with retinal fluid despite frequent anti-VEGF injections (MERLIN). https:\/\/www.clinicaltrialsgov\/ct2\/show\/NCT03710564."},{"key":"2465_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14712598.2022.2028772","volume":"22","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab horizontal line termination of 4 weekly trials horizontal line rebalancing the immunogenicity risk. Expert Opin Biol Ther. 2022;22:441\u20133.","journal-title":"Expert Opin Biol Ther"},{"key":"2465_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","volume":"138","author":"SSA Kondapalli","year":"2020","unstructured":"Kondapalli SSA. Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity. JAMA Ophthalmol. 2020;138:1103\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"2465_CR19","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41433-020-01324-w","volume":"35","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab-foreseeable workflow in the current scenario. Eye (Lond). 2021;35:1548\u201350.","journal-title":"Eye (Lond)"},{"key":"2465_CR20","doi-asserted-by":"publisher","first-page":"P259","DOI":"10.1016\/j.ophtha.2019.09.028","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal and ophthalmic artery occlusions preferred practice pattern(R). Ophthalmology. 2020;127:P259\u201387.","journal-title":"Ophthalmology"},{"key":"2465_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12348-019-0176-9","volume":"9","author":"VLS Dingerkus","year":"2019","unstructured":"Dingerkus VLS, Munk MR, Brinkmann MP, et al. Optical coherence tomography angiography (OCTA) as a new diagnostic tool in uveitis. J Ophthalmic Inflamm Infect. 2019;9:10.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2465_CR22","doi-asserted-by":"crossref","first-page":"251584142091778","DOI":"10.1177\/2515841420917781","volume":"12","author":"A Marchese","year":"2020","unstructured":"Marchese A, Agarwal A, Moretti AG, et al. Advances in imaging of uveitis. Ther Adv Ophthalmol. 2020;12:2515841420917781.","journal-title":"Ther Adv Ophthalmol"},{"key":"2465_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12886-019-1209-8","volume":"19","author":"JH Park","year":"2019","unstructured":"Park JH, Lee SY, Lee EK. Morphological characteristics of ocular toxoplasmosis and its regression pattern on swept-source optical coherence tomography angiography: a case report. BMC Ophthalmol. 2019;19:199.","journal-title":"BMC Ophthalmol"},{"key":"2465_CR24","first-page":"1","volume":"21","author":"A Agarwal","year":"2021","unstructured":"Agarwal A, Bhatt S, Keshari S, et al. Retinal microvascular alterations in patients with Quiescent Posterior and Panuveitis using optical coherence Tomography Angiography. Ocul Immunol Inflamm. 2021;21:1\u20137.","journal-title":"Ocul Immunol Inflamm."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02465-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:26:37Z","timestamp":1654255597000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02465-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02465-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"type":"electronic","value":"1471-2415"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case was approved by the Institutional Review Board of Seoul National University Hospital (IRB approval number: 2019\u2013101-1255).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}